Intellia Therapeutics Inc (FRA:38I)
€ 13.565 -0.175 (-1.27%) Market Cap: 1.44 Bil Enterprise Value: 903.64 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 57/100

Intellia Therapeutics Inc Call to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Corporate Call Transcript

Jun 28, 2021 / 12:00PM GMT
Release Date Price: €102.8 (+39.48%)
Operator

Good morning, and welcome to Intellia Therapeutics Investor Event to discuss the Interim Clinical Data from the Phase I Study of NTLA-2001. This conference is being recorded at the company's request and will be available on the company's website following the end of the call.

I will now turn the conference over to Lina Li, Director of Investor Relations at Intellia. Please proceed.

Lina Li
Intellia Therapeutics, Inc. - Director of IR

Thank you, operator, and good morning, everyone. Welcome to Intellia's investor event featuring interim data from our Phase I clinical trial of NTLA-2001. Saturday morning, we issued a press release detailing results presented at the 2021 Peripheral Nerve Society's Annual Meeting and published in the New England Journal of Medicine. This release and the accompanying presentation can be found on the Investors & Media section of Intellia's website at intelliatx.com. As a reminder, this call is being broadcast live, and a replay of the event will be archived on the company's website.

Before we begin, allow me

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot